The study will enrol SARS-Cov-2 positive patients with moderate to severe ARDS admitted to an Intensive Care Unit (ICU) and under mechanical ventilation*. To be eligible to participate in this study, an individual must meet all the following criteria: 1. Informed consent, if possible. 2. Male or female ≥18 years of age. 3. Laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen. 4. Patient has been admitted to an ICU, is mechanically ventilated (according to the ventilation and weaning protocol as outlined in Appendix I) and stable in this condition for at least 8 hours. 5. Moderate and severe ARDS diagnosis as defined by the Berlin Definition: Onset of ARDS within 1 week of a known clinical insult or new or worsening respiratory symptoms Bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules Respiratory failure not fully explained by cardiac failure or fluid overload (origin of oedema) PaO2/FiO2 < 200 mm Hg continuously observed for a period of ≥4hours (≥2 ABG analyses during that time, with the last value obtained shortly prior to randomization), minimum PEEP ≥8 cm H2O 6. Time from intubation to randomization ≤ 96h

The study will enrol SARS-Cov-2 positive patients with moderate to severe ARDS admitted to an Intensive Care Unit (ICU) and under mechanical ventilation*. To be eligible to participate in this study, an individual must meet all the following criteria: 1. Informed consent, if possible. 2. Male or female ≥18 years of age. 3. Laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen. 4. Patient has been admitted to an ICU, is mechanically ventilated (according to the ventilation and weaning protocol as outlined in Appendix I) and stable in this condition for at least 8 hours. 5. Moderate and severe ARDS diagnosis as defined by the Berlin Definition: Onset of ARDS within 1 week of a known clinical insult or new or worsening respiratory symptoms Bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules Respiratory failure not fully explained by cardiac failure or fluid overload (origin of oedema) PaO2/FiO2 < 200 mm Hg continuously observed for a period of ≥4hours (≥2 ABG analyses during that time, with the last value obtained shortly prior to randomization), minimum PEEP ≥8 cm H2O 6. Time from intubation to randomization ≤ 96h

The study will enrol SARS-Cov-2 positive patients with moderate to severe ARDS admitted to an Intensive Care Unit (ICU) and under mechanical ventilation*. To be eligible to participate in this study, an individual must meet all the following criteria: 1. Informed consent, if possible. 2. Male or female ≥18 years of age. 3. Laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen. 4. Patient has been admitted to an ICU, is mechanically ventilated (according to the ventilation and weaning protocol as outlined in Appendix I) and stable in this condition for at least 8 hours. 5. Moderate and severe ARDS diagnosis as defined by the Berlin Definition: Onset of ARDS within 1 week of a known clinical insult or new or worsening respiratory symptoms Bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules Respiratory failure not fully explained by cardiac failure or fluid overload (origin of oedema) PaO2/FiO2 < 200 mm Hg continuously observed for a period of ≥4hours (≥2 ABG analyses during that time, with the last value obtained shortly prior to randomization), minimum PEEP ≥8 cm H2O 6. Time from first meeting diagnostic ARDS criteria to randomization ≤ 96h

The study will enrol SARS-Cov-2 positive patients with moderate to severe ARDS admitted to an Intensive Care Unit (ICU) and under mechanical ventilation*. To be eligible to participate in this study, an individual must meet all the following criteria: 1. Informed consent, if possible. 2. Male or female ≥18 years of age. 3. Laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen. 4. Patient has been admitted to an ICU, is mechanically ventilated (according to the ventilation and weaning protocol as outlined in Appendix I) and stable in this condition for at least 8 hours. 5. Moderate and severe ARDS diagnosis as defined by the Berlin Definition: Onset of ARDS within 1 week of a known clinical insult or new or worsening respiratory symptoms Bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules Respiratory failure not fully explained by cardiac failure or fluid overload (origin of oedema) PaO2/FiO2 < 200 mm Hg continuously observed for a period of ≥4hours (≥2 ABG analyses during that time, with the last value obtained shortly prior to randomization), minimum PEEP ≥8 cm H2O 6. Time from first meeting diagnostic ARDS criteria to randomization ≤ 96h

The study will enrol SARS-Cov-2 positive patients with moderate to severe ARDS admitted to an Intensive Care Unit (ICU) and under mechanical ventilation*. To be eligible to participate in this study, an individual must meet all the following criteria: 1. Informed consent, if possible. 2. Male or female ≥18 years of age. 3. Laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen. 4. Patient has been admitted to an ICU, is mechanically ventilated (according to the ventilation and weaning protocol as outlined in Appendix I) and stable in this condition for at least 8 hours. 5. Moderate and severe ARDS diagnosis as defined by the Berlin Definition: Onset of ARDS within 1 week of a known clinical insult or new or worsening respiratory symptoms Bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules Respiratory failure not fully explained by cardiac failure or fluid overload (origin of oedema) PaO2/FiO2 < 200 mm Hg continuously observed for a period of ≥4hours (≥2 ABG analyses during that time, with the last value obtained shortly prior to randomization), minimum PEEP ≥8 cm H2O 6. Time from intubation to randomization ≤ 96h

The study will enrol SARS-Cov-2 positive patients with moderate to severe ARDS admitted to an Intensive Care Unit (ICU) and under mechanical ventilation*. To be eligible to participate in this study, an individual must meet all the following criteria: 1. Informed consent, if possible. 2. Male or female ≥18 years of age. 3. Laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen. 4. Patient has been admitted to an ICU, is mechanically ventilated (according to the ventilation and weaning protocol as outlined in Appendix I) and stable in this condition for at least 8 hours. 5. Moderate and severe ARDS diagnosis as defined by the Berlin Definition: Onset of ARDS within 1 week of a known clinical insult or new or worsening respiratory symptoms Bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules Respiratory failure not fully explained by cardiac failure or fluid overload (origin of oedema) PaO2/FiO2 < 200 mm Hg continuously observed for a period of ≥4hours (≥2 ABG analyses during that time, with the last value obtained shortly prior to randomization), minimum PEEP ≥8 cm H2O 6. Time from intubation to randomization ≤ 96h

The study will enrol SARS-Cov-2 positive patients with moderate to severe ARDS admitted to an Intensive Care Unit (ICU) and under mechanical ventilation*. To be eligible to participate in this study, an individual must meet all the following criteria: 1. Informed consent, if possible. 2. Male or female ≥18 years of age. 3. Laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen. 4. Patient has been admitted to an ICU, is mechanically ventilated (according to the ventilation and weaning protocol as outlined in Appendix I) and stable in this condition for at least 8 hours. 5. Moderate and severe ARDS diagnosis as defined by the Berlin Definition: Onset of ARDS within 1 week of a known clinical insult or new or worsening respiratory symptoms Bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules Respiratory failure not fully explained by cardiac failure or fluid overload (origin of oedema) PaO2/FiO2 < 200 mm Hg continuously observed for a period of ≥4hours (≥2 ABG analyses during that time, with the last value obtained shortly prior to randomization), minimum PEEP ≥8 cm H2O 6. Time from first meeting diagnostic ARDS criteria to randomization ≤ 96h

The study will enrol SARS-Cov-2 positive patients with moderate to severe ARDS admitted to an Intensive Care Unit (ICU) and under mechanical ventilation*. To be eligible to participate in this study, an individual must meet all the following criteria: 1. Informed consent, if possible. 2. Male or female ≥18 years of age. 3. Laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen. 4. Patient has been admitted to an ICU, is mechanically ventilated (according to the ventilation and weaning protocol as outlined in Appendix I) and stable in this condition for at least 8 hours. 5. Moderate and severe ARDS diagnosis as defined by the Berlin Definition: Onset of ARDS within 1 week of a known clinical insult or new or worsening respiratory symptoms Bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules Respiratory failure not fully explained by cardiac failure or fluid overload (origin of oedema) PaO2/FiO2 < 200 mm Hg continuously observed for a period of ≥4hours (≥2 ABG analyses during that time, with the last value obtained shortly prior to randomization), minimum PEEP ≥8 cm H2O 6. Time from first meeting diagnostic ARDS criteria to randomization ≤ 96h